Needham Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $357

Benzinga Newsdesk www.benzinga.com Neutral 48.3%

Neg 0% Neu 48.3% Pos 0%

Needham analyst Joseph Stringer maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $510 to $357.